Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreichs Ataxia
January 23, 2025 16:05 ET | Source: Larimar Therapeutics Adolescents receive a…
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreichs Ataxia
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting…